110 related articles for article (PubMed ID: 19596960)
1. Docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer.
Tsutani Y; Ohara M; Suzuki T; Minami K; Miyahara E; Kameda A; Noso Y
Anticancer Res; 2009 Jul; 29(7):2775-9. PubMed ID: 19596960
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
3. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
Shigeyasu K; Kagawa S; Uno F; Nishizaki M; Kishimoto H; Gochi A; Kimura T; Takahata T; Nonaka Y; Ninomiya M; Fujiwara T
Cancer Chemother Pharmacol; 2013 Apr; 71(4):937-43. PubMed ID: 23355040
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Kakeji Y; Oki E; Egashira A; Sadanaga N; Takahashi I; Morita M; Emi Y; Maehara Y
Oncology; 2009; 77(1):49-52. PubMed ID: 19556809
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Kunisaki C; Takahashi M; Makino H; Oshima T; Fujii S; Takagawa R; Kimura J; Kosaka T; Ono HA; Akiyama H; Kameda K; Kito F; Morita S; Endo I
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1363-8. PubMed ID: 20803016
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Hironaka S; Yamazaki K; Taku K; Yokota T; Shitara K; Kojima T; Ueda S; Machida N; Muro K; Boku N
Jpn J Clin Oncol; 2010 Nov; 40(11):1014-20. PubMed ID: 20603245
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
Zang DY; Yang DH; Lee HW; Hwang SW; Song HH; Jung JY; Kwon JH; Kim HJ; Kim JH; Park SR; Kim MJ; Jang KM; Park CK; Kim JH; Lee BH
Cancer Chemother Pharmacol; 2009 Feb; 63(3):509-16. PubMed ID: 18481067
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy.
Fujitani K; Tsujinaka T; Yamasaki H; Hirao M; Yoshida K; Kurokawa Y
Anticancer Res; 2009 Aug; 29(8):3385-91. PubMed ID: 19661361
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
19. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
Ozaki T; Tamura K; Satoh T; Kurata T; Shimizu T; Miyazaki M; Okamoto I; Nakagawa K; Fukuoka M
Anticancer Res; 2007; 27(4C):2657-65. PubMed ID: 17695429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
